GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Up 112.3% in January

GeoVax Labs Inc. (NASDAQ:GOVX) saw a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 321,661 shares, an increase of 112.3% from the January 15th total of 151,504 shares. Currently, 18.7% of the company’s stock are sold short. Based on an average daily trading volume, of 201,570 shares, the short-interest ratio is currently 1.6 days. Based on an average daily trading volume, of 201,570 shares, the short-interest ratio is currently 1.6 days. Currently, 18.7% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on GOVX shares. Wall Street Zen lowered GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. D. Boral Capital reiterated a “buy” rating on shares of GeoVax Labs in a report on Wednesday, January 21st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $187.50.

Institutional Investors Weigh In On GeoVax Labs

Several large investors have recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in shares of GeoVax Labs in the 1st quarter worth approximately $27,000. HRT Financial LP purchased a new stake in GeoVax Labs in the fourth quarter worth $31,000. Hudson Bay Capital Management LP bought a new stake in shares of GeoVax Labs in the third quarter valued at $47,000. Renaissance Technologies LLC purchased a new position in shares of GeoVax Labs during the 4th quarter valued at $104,000. Finally, Armistice Capital LLC purchased a new position in shares of GeoVax Labs during the 3rd quarter valued at $253,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Price Performance

Shares of NASDAQ:GOVX opened at $2.31 on Friday. GeoVax Labs has a 1 year low of $2.28 and a 1 year high of $47.13. The company has a market capitalization of $4.00 million, a PE ratio of -0.07 and a beta of 3.77. The business has a fifty day moving average price of $4.56 and a two-hundred day moving average price of $11.47.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($7.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.00) by ($1.75). GeoVax Labs had a negative return on equity of 489.67% and a negative net margin of 403.88%. Sell-side analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.